# Enodia Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/enodia-therapeutics

- Industry: Biotechnology
- Headquarters: Paris, France
- Website: www.enodiatx.com
- Total disclosed funding: $24M
- Latest round: Seed (Dec 9, 2025)
- Investors on record: 10

## About

Based in France, Enodia Therapeutics specializes in developing innovative small-molecule therapies for the targeted degradation of proteins responsible for immuno-inflammatory disorders.Founded in 2025, Enodia Therapeutics operates from its headquarters in Paris, France, developing therapies focused on immuno-inflammatory diseases. In December 2025, Enodia Therapeutics raised EUR 20.7 million in seed funding co-led by  Elaia Partners, Pfizer Venture Investments, and Bpifrance, with participation from Wallonie Entreprendre, Argobio SAS, MACSF, Institut Pasteur, InvestSud, Sambrinvest, and Mission BioCapital. This marks their first deal in the funding landscape.Enodia Therapeutics specializes in the development of small-molecule therapies designed for the selective degradation of disease-driving proteins, focusing on immuno-inflammatory disorders. Their approach targets the initiation of protein synthesis to eliminate pathogenic proteins before they mature and contribute to disease progression. This innovative strategy leverages the Sec61 translocon, which is crucial for the translocation of secretory and transmembrane proteins across the endoplasmic reticulum membrane. Enodia's core offerings aim to address inflammatory and autoimmune diseases, with research originating from the Institut Pasteur and development supported by Argobio. The company actively markets its solutions and therapies primarily across European and North American healthcare sectors, targeting pharmaceutical companies and research institutions engaged in biotechnology and therapeutic development.Enodia Therapeutics generates revenue through strategic partnerships and collaborations with leading investors and pharmaceutical companies. The company’s transaction structure primarily involves B2B relationships, focusing on partnerships that facilitate the advancement of its targeted protein degradation platform. These collaborations may encompass funding arrangements for research and development, co-development agreements for clinical trials, and potential licensing deals for the commercialization of its novel therapies. Enodia’s revenue model includes milestone payments tied to the successful development stages of its products and royalties on sales once therapies reach the market. As they continue to secure funding—such as the recent EUR 20.7 mn raised for their small-molecule platform—the financial foundation is strengthened for further development and potential commercialization of their leading-edge therapeutic solutions.Enodia Therapeutics is set to utilize the EUR 20.7 mn raised in Seed funding to further develop its small-molecule platform, enhancing its capabilities in targeting immuno-inflammatory disorders. The company aims to introduce new therapies designed for specific conditions within the next two years, while also planning to expand its market reach into additional European and North American regions by 2026. The funding will support research and development initiatives, ensuring the advancement of their innovative solutions in the competitive biopharmaceutical landscape.

## Funding rounds

- Seed, Dec 9, 2025, $24M — Elaia Partners, MACSF, Institut Pasteur, Pfizer Venture Investments, Sambrinvest, Bpifrance Investissement, Mission Biocapital, Argobio SAS, Investsud, Wallonie Entreprendre

## Investors

- Elaia Partners (https://capitalatlas.ai/funds/elaia-partners) — Seed
- MACSF — Seed
- Institut Pasteur — Seed
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Seed
- Sambrinvest (https://capitalatlas.ai/funds/sambrinvest) — Seed
- Bpifrance Investissement (https://capitalatlas.ai/funds/bpifrance-investissement) — Seed
- Mission Biocapital (https://capitalatlas.ai/funds/mission-biocapital) — Seed
- Argobio SAS — Seed
- Investsud — Seed
- Wallonie Entreprendre — Seed